|
Microorganism | Strain | Model/inoculation | Dose/route of administration | Reference |
|
E. faecium | HM-952 | C57BL/6 mice/oral inoculation | 10 mg/kg/oral administration | [58] |
C. difficile | 630 | Swiss Webster mice/oral gavage | 100 mg/kg/oral administration | [60] |
S. aureus | Clinical | Sprague Dawley rats/skin infection | 25 mg/kg/intradermal administration | [55] |
A. baumanii | Clinical | Kunming mice urinary tract infection | 25 mg/kg Ebs plus 6 mg/kg Ag+/intraperitoneal administration | [62] |
Y. pseudotuberculosis | Yp III | Kunming mice gastroenteritis/intragastric gavage | 20 mg/kg Ebs plus 5 mg/kg Ag+/intraperitoneal administration | [63] |
S. aureus | MRSA USA300 | Obese and diabetic TALLYHO/JngJ mice/infections of pressure ulcers | 2%/topical administration | [57] |
S. aureus | MRSA USA300 | Caenorhabditis elegans AU37 (L4-stage worms) | 8 μg/mL/immersion in 96-well plates | [52] |
S. aureus | MRSA USA300 | BALB/c mice skin infection/intradermal inoculation | 1-2%/topical administration | [16] |
E. coli | BC1 (UPEC) | BALB/c mice cystitis/bladders infected via transurethral catheterization | 5 mg/kg Ebs plus 6 mg/kg Ag+/intraperitoneal administration | [64] |
E. coli | ZY-1 (MDR) | Kunming mice peritonitis/intraperitoneal injection | 25 mg/kg Ebs plus 6 mg/kg Ag+/intraperitoneal administration | [65] |
S. aureus | MRSA USA200 | BALB/c mice peritonitis/intraperitoneal injection | 30 mg/kg/intraperitoneal administration | [53] |
|